As a woman diagnosed with metastatic breast cancer (MBC), a lot may have changed – but a lot hasn’t.
IBRANCE® is the #1 prescribed, FDA-approved oral combination treatment for women with HR+, HER2- MBC.
FDA-approved oral combination
treatment for women with HR+,
HER2- metastatic breast cancer.
INDICATIONS: IBRANCE is a prescription medicine used to treat HR+, HER2- breast cancer that has spread to other parts of the body (metastatic) in combination with an aromatase inhibitor as the first hormonal based therapy in women who have gone through menopause, or fulvestrant in women with disease progression following hormonal therapy.
FINANCIAL ASSISTANCE If you can’t afford your medicine, we’re here to help by assisting with co-pays* or providing IBRANCE for free to eligible patients.
SUPPORT BEYOND TREATMENT At Pfizer Oncology Together, we’re here to help. One of our Care Champions will help you get the support you need—all in one place.
Limits, terms, and conditions apply. Patients may receive up to $25,000 in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. For more information, please call
IBRANCE Answers delivers facts and resources to help you understand more about IBRANCE and find helpful support throughout treatment.